Skip to main content
Clinical Trials/CTRI/2019/08/020629
CTRI/2019/08/020629
Completed
未知

An Observational, Cross sectional Study to assess the Prevalence of Heart Failure in Type 2 Diabetes Patients in India - H F Registry

AstraZeneca Pharma India Ltd0 sites621 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Sponsor
AstraZeneca Pharma India Ltd
Enrollment
621
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
October 14, 2021
Last Updated
last year
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Both men and women aged \= 18 years
  • 2\.Diagnosed with type 2 diabetes (as per ADA Criteria \[Annexure 1])
  • 3\.Duration of diabetes for 1 year or more
  • 4\.Willing to provide written informed consent

Exclusion Criteria

  • 1\.Patients with evidence of coronary artery disease – CAD (based on the clinical expertise of the physician)
  • 2\.Patients who were previously diagnosed with heart failure
  • 3\. Patients with evidence of valvular disease based on clinical judgement of the Principle Investigator (PI).
  • 4\.Current treatment with digoxin
  • 5\.History or symptoms of peripheral artery disease, chronic obstructive pulmonary disease and arrhythmias
  • 6\.Patients diagnosed with stage III/IV Chronic Kidney Disease (CKD)
  • 7\.Diabetes other than type 2 diabetes mellitus

Outcomes

Primary Outcomes

Not specified

Similar Trials